Detalles de la búsqueda
1.
Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration.
Int J Retina Vitreous
; 9(1): 8, 2023 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36726178
2.
One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents.
Clin Ophthalmol
; 17: 3601-3611, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38026599
Resultados
1 -
2
de 2
1
Próxima >
>>